Johnson & Johnson Announces First Data From Phase 3 PERSEUS Study Highlighting DARZALEX FASPRO-Based Quadruplet Therapy Regimen Shows Significant Improvement In Outcomes For Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced significant clinical improvement in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients using DARZALEX FASPRO-based therapy. The Phase 3 PERSEUS study showed a 58% reduction in disease progression or death risk compared to standard care. The study, presented at ASH 2023 and published in The New England Journal of Medicine, demonstrated higher complete response rates and minimal residual disease negativity with DARZALEX FASPRO. The safety profile was consistent with known profiles for daratumumab and VRd. Overall survival data are not yet mature but are trending favorably.
December 12, 2023 | 5:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's DARZALEX FASPRO-based therapy shows promising results in a Phase 3 study, potentially improving the standard of care for multiple myeloma and reinforcing the company's oncology portfolio.
The positive results from the PERSEUS study are likely to increase investor confidence in Johnson & Johnson's oncology portfolio, potentially leading to an increase in stock price in the short term. The data supports DARZALEX FASPRO as a new standard of care, which could lead to increased sales and market share in the treatment of multiple myeloma. The relevance is high as the news is directly about Johnson & Johnson's product, and the importance is significant due to the potential impact on the company's revenue and market position in oncology.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100